
Tempest Therapeutics, Inc. (TPST) Stock Ticker
TPST right now
Market factors today
Unlock the full TPST picture
About Tempest Therapeutics, Inc.
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
TPST stock facts
| Ticker symbol | TPST |
| Exchange | NASDAQ Capital Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $13.2M |
| CEO | Matthew Angel |
| Employees | 4 |
| Headquarters | Brisbane, CA, US |
| IPO date | 2012-11-12 |
| Website | www.tempesttx.com |
What you can see for TPST on Tickr
Live TPST price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the TPST report.
Rankings
FAQ
What is the ticker symbol for Tempest Therapeutics, Inc.?
The ticker symbol for Tempest Therapeutics, Inc. is TPST, listed on the NASDAQ Capital Market.
What is TPST?
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial…